Filing Analysis
Raphael Pharmaceutical Inc. announced a significant leadership overhaul involving the voluntary resignations of its Chairman and both its CFO and General Counsel. The company has appointed Uri Tadelis as the new Chief Financial Officer to fill the vacancy left by Guy Ofir.
🚩 Red Flags
- Simultaneous departure of Chairman, CFO, and General Counsel creates significant leadership instability.
- Loss of dual-role officer (CFO/General Counsel) can disrupt both financial oversight and legal compliance functions in a micro-cap environment.
- Rapid succession of departures within a single month (June 30 to July 16).
📋 Key Facts
- Ajay Kumar Dhadha resigned as Chairman of the Board and Director, effective June 30, 2026.
- Guy Ofir resigned as CFO, General Counsel, and Director, effective July 16, 2026.
- Uri Tadelis appointed as Chief Financial Officer, effective July 16, 2026.
- The company stated that the resignations were voluntary and not due to disagreements regarding operations, policies, financial reporting, or management.
Raphael Pharmaceutical Inc. announced a change in its Board of Directors involving the resignation of Dr. Igal Louria Hayon from the Board and the appointment of Mr. Zvi Laufer Laor to fill the vacancy.
🚩 Red Flags
- None identified; resignation was explicitly stated as not related to disagreements with management or operations.
📋 Key Facts
- Dr. Igal Louria Hayon resigned from the Board effective August 1, 2025.
- The resignation was not due to any disagreement regarding Company operations, policies, or practices.
- Mr. Hayon will continue his role as Chief Technology Officer (CTO) under an existing service agreement.
- Mr. Zvi Laufer Laor was appointed to the Board on August 7, 2025, to fill the vacancy.
- Mr. Laufer is a lawyer specializing in business and commercial law since 1979.
Raphael Pharmaceutical Inc. announced the completion of product development and readiness to launch its proprietary natural formula, 'RaphaWell,' a dietary supplement for rheumatoid arthritis (RA) support in the U.S. market.
🚩 Red Flags
- Forward-looking statements regarding commercial potential and market advantage carry inherent risks of failure in the wellness/supplement sector.
📋 Key Facts
- Completed product development for 'RaphaWell' brand as of August 7, 2025.
- Product is a 100% natural, plant-based dietary supplement targeting rheumatoid arthritis (RA) support.
- Clinical study results showed pain levels dropped from 75% to 50% and morning stiffness reduced from 75% to 41.67% over an 8-week period.
- The company intends to engage a U.S.-based manufacturer to scale production.
- Product will be sold as a standalone dietary supplement with clinical data accessible via QR code on packaging.
Raphael Pharmaceutical Inc. announced a change in its Board leadership on January 8, 2025. Ajay Kumar Dhadha has been appointed to the Board and elected as Chairman, replacing Shlomo Pilo in that capacity.
🚩 Red Flags
- Change in Board leadership/Chairman role can sometimes signal shifts in corporate governance or strategic direction, though no specific reason was provided for Mr. Pilo's replacement as Chairman.
📋 Key Facts
- Ajay Kumar Dhadha appointed to the Board of Directors effective January 8, 2025.
- Mr. Dhadha selected as Chairman of the Board, replacing Mr. Shlomo Pilo.
- The Board size was increased by one member to accommodate this appointment.
- Mr. Dhadha is the founder and CEO of Shanti Gems (1982) Ltd., a diamond export company.
Raphael Pharmaceutical reported successful proof-of-concept clinical study results for its cannabinoid-based formula in treating Rheumatoid Arthritis (RA). The study showed improvements in patient pain, sleep quality, and disease activity scores (DAS28) over an 8-week period.
🚩 Red Flags
- Small sample size (n=12) limits statistical significance and generalizability.
- Lack of statistically significant changes in blood biomarkers despite subjective improvements.
- Single-group study design lacks a control group, increasing risk of placebo effect.
📋 Key Facts
- Study evaluated Raphael's Formula in 12 adult participants with active Rheumatoid Arthritis (RA).
- Disease Activity Score (DAS28) decreased by 19.2%, moving patients from high to moderate disease activity.
- Remission rates increased from 0% at baseline to 16.67% at week 8.
- High disease activity prevalence dropped from 66.67% to 41.67%.
- Pain reporting decreased from 75% of participants to 50% by week 8.
- 91.7% of participants indicated they would recommend the formula to others with RA.
- Blood biomarker analysis showed no statistically significant changes.
Raphael Pharmaceutical Inc. has dismissed its previous auditor, Weinstein International CPA, and appointed Elkana Amitai CPA on a short-term basis for the upcoming quarter. The dismissal follows an explanatory paragraph in the former auditor's report regarding substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language: The former auditor's report included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- Auditor change combined with going concern warning (Red Flag Escalator).
- Short-term engagement of new auditor suggests potential instability or difficulty in securing long-term audit services.
📋 Key Facts
- Dismissal of Weinstein International CPA (Former Auditor) effective September 5, 2024.
- Appointment of Elkana Amitai CPA (New Auditor) for the quarter ending September 30, 2024.
- The engagement with the New Auditor is on a short-term basis to allow time to evaluate long-term audit needs.
- Former auditor's reports for FY2022 and FY2023 contained no adverse opinions or disclaimers of opinion.
- No disagreements regarding accounting principles, practices, or auditing scope were reported between the Company and the Former Auditor.
Raphael Pharmaceutical Inc. has filed Amended and Restated Articles of Incorporation to significantly increase its authorized share count. This move prepares the company for potential future equity financing or capital restructuring.
🚩 Red Flags
- Significant increase in authorized shares can lead to future dilution for existing shareholders if used for a secondary offering.
📋 Key Facts
- Increased authorized shares from 21,020,560 to 50,000,000 on June 26, 2024.
- The change was approved by the Board of Directors on May 9, 2024.
- Shareholders (majority) approved the change on May 22, 2024.
- Common stock par value remains $0.01 per share.
Raphael Pharmaceutical Inc. announced the commencement of a proof-of-concept clinical trial in the United States to evaluate the efficacy of Cannabigerol for patients with active Rheumatoid Arthritis (RA). The company has partnered with Citruslabs to oversee the trial, which is expected to last approximately six months from the first participant's recruitment.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Commenced proof-of-concept clinical trial in the US on April 30, 2024.
- Target indication: Rheumatoid Arthritis (RA).
- Therapeutic agent: Cannabigerol.
- Partnered with MindMate, Inc. / dba Citruslabs to oversee the trial.
- Estimated timeline for completion is six months from first participant recruitment.